Early fibrosis treatment for non-progressive lung scarring
Part of Lungs & breathing clinical trials.
This trial tests whether starting anti-scarring medication early helps people with a type of lung scarring called fibrotic interstitial lung disease (ILD) that hasn't gotten worse. The goal is to see if it can prevent further damage and improve breathing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 85 years old
- You have been diagnosed with fibrotic lung scarring (ILD) that hasn't progressed in the last year despite usual treatments
- You have mild to moderate breathing issues based on lung function tests (FVC and DLCO)
- You weigh at least 110 lbs for men or 88 lbs for women
- You do not have idiopathic pulmonary fibrosis (IPF) or progressive scarring (PPF)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how to find and treat fibrotic interstitial lung disease (a condition where lung tissue becomes scarred and stiff) as early as possible. It may help people with this type of lung disease get better care.
This study follows patients with chronic lung scarring (fibrosing interstitial lung disease) who are in the intensive care unit for severe breathing failure. It aims to better understand their condition and care, which may help improve future treatments.
This study is for people with a specific type of lung scarring (not IPF) to understand how the disease progresses. Researchers will collect detailed health information, imaging, and blood samples to learn more about the condition.
This study looks at how to better treat different types of lung scarring (fibrotic ILD) by focusing on each person's specific problems. It is for adults who are already being treated for a fibrotic ILD at one of two hospitals in Perth, Australia.
This study uses a single lung scan to find early signs of progressive scarring (fibrosis) in people with pulmonary fibrosis. It may help doctors predict which patients will get worse faster.
This study tests whether a new drug called nerandomilast can slow down scarring in the lungs for people with certain types of fibrosing interstitial lung disease (a condition where lung tissue becomes thick and scarred). You may qualify if you have lung scarring that is getting worse and haven't tried this or similar drugs before.
Hear when a new Fibrotic Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.